

1 **Safety and effectiveness of COVID-19 mRNA vaccination and risk factors for**  
2 **hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide**  
3 **cohort study in Sweden**

4

5 Prof. Peter Nordström, PhD<sup>1</sup>, Marcel Ballin, MSc<sup>1</sup>, Anna Nordström, PhD<sup>1,2,3</sup>

6 <sup>1</sup>Department of Community Medicine and Rehabilitation, Unit of Geriatric Medicine, Umeå

7 University, Umeå, Sweden

8 <sup>2</sup>Department of Public Health and Clinical Medicine, Section of Sustainable Health, Umeå

9 University, Umeå, Sweden

10 <sup>3</sup>School of Sport Sciences, UiT the Arctic University of Norway, Tromsø, Norway

11

12 **Corresponding author:**

13 Peter Nordström, Professor

14 Unit of Geriatric Medicine

15 Department of Community Medicine and Rehabilitation

16 Umeå University

17 90187 Umeå

18 Sweden

19 Phone: +4670 899 65 99

20 E-mail: [peter.nordstrom@umu.se](mailto:peter.nordstrom@umu.se)

21

22

23

24

25

26

## 27 **Abstract**

### 28 **Background**

29 Real-world evidence on the safety and effectiveness of COVID-19 vaccination against severe  
30 disease caused by the omicron variant among adolescents is sparse. In addition, evidence on  
31 risk factors for severe COVID-19 disease, and whether vaccination is similarly effective in  
32 such risk groups, is unclear.

### 33 **Methods and findings**

34 Nationwide registers were used to examine the safety and effectiveness of COVID-19 mRNA  
35 vaccination against COVID-19 hospitalisation, and risk factors for COVID-19 hospitalisation  
36 in adolescents. The safety analysis included all individuals in Sweden born between 2003-  
37 2009 (aged 11.3-19.2 years) given at least one dose of mRNA vaccine (N=645,355), and  
38 never vaccinated controls (N=199,022). Outcomes evaluated included all hospitalisations  
39 until 5 June 2022. The vaccine effectiveness (VE) against COVID-19 hospitalisation and  
40 associated risk factors was evaluated in adolescents given two doses of mRNA vaccine  
41 (N=501,945), as compared to never vaccinated controls (N=170,083), during an omicron  
42 predominant period (1 January 2022 to 5 June 2022). The safety analysis showed that  
43 COVID-19 mRNA vaccination was not associated with an increased risk of any serious  
44 adverse events resulting in hospitalisation. During follow-up, 1.69% of the vaccinated  
45 individuals were hospitalised compared to 1.71% of the controls (P=0.29). In the VE analysis,  
46 there were 21 cases (0.004%) of COVID-19 hospitalisation among 2-dose recipients and 26  
47 cases (0.015%) among controls, resulting in an estimated VE of 75% (95% CI, 54-86,  
48 P<0.001). Strong risk factors for COVID-19 hospitalisation included previous infections  
49 (odds ratio [OR], 14.3, 95% CI, 7.7-26.6, P<0.001), and cerebral palsy/development disorders  
50 (OR, 12.0, 95% CI, 6.4-22.6, P<0.001), with similar estimates of VE in these subgroups as in  
51 the total cohort. The number needed to vaccinate with two doses to prevent one case of

52 COVID-19 hospitalisation was 9,007 in the total cohort and 1,031 in those with previous  
53 infections or developmental disorders. None of the individuals hospitalised due to COVID-19  
54 died within 30 days.

## 55 **Conclusions**

56 In this nationwide study, COVID-19 mRNA vaccination was not associated with an increased  
57 risk of any serious adverse event in adolescents. Two doses were associated with a lower risk  
58 of COVID-19 hospitalisation during the omicron predominant period, especially among those  
59 with certain predisposing conditions who should be prioritized for vaccination. However,  
60 COVID-19 hospitalisation among general adolescents was extremely rare, and additional  
61 doses in this population may not be warranted at this stage.

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

## 77 **Why was this study done**

### 78 **Evidence before this study**

- 79 ➤ There is limited evidence on the effectiveness of COVID-19 vaccination against  
80 severe outcomes during the omicron era among adolescents. In addition, there is lack  
81 of data on whether certain groups of adolescents are at greater risk of severe COVID-  
82 19 and should be prioritized in vaccination programs, and whether vaccination is  
83 equally effective in such risk groups.
- 84 ➤ Regarding safety, some studies have indicated a link between COVID-19 mRNA  
85 vaccination and increased risk of myocarditis and pericarditis in young men, although  
86 the data appear inconsistent.

### 87 **What did the researchers do and find?**

- 88 ➤ Using Swedish nationwide health registers, a cohort of 844,377 adolescents were  
89 followed until 5 June 2022 to evaluate the safety and effectiveness of COVID-19  
90 mRNA vaccination against COVID-19 hospitalisation, and risk factors for COVID-19  
91 hospitalisation.
- 92 ➤ COVID-19 mRNA vaccination in adolescents was not associated with an increased  
93 risk of any diagnoses resulting in hospitalisation. In contrast, two doses of vaccine had  
94 an associated 75% effectiveness against COVID-19 hospitalisation. However, only  
95 about 6 individuals in 100,000 were hospitalised due to COVID-19 during follow-up .
- 96 ➤ There were certain strong risk factors for COVID-19 hospitalisation, such as previous  
97 infections and different development disorders, which increased the risk of COVID-19  
98 hospitalisation more than tenfold. Vaccine effectiveness among these individuals was  
99 similar as in the rest of the cohort.

### 100 **What do these findings mean?**

101       ➤ Although COVID-19 mRNA vaccination appears safe and associated with reduced  
102       risk of COVID-19 hospitalisation, the risk of severe COVID-19 seems to be extremely  
103       low in general adolescents. Therefore, administration of additional doses to the  
104       general population of adolescents may not be warranted at this stage of the pandemic.  
105       In contrast, individuals with a high risk for severe COVID-19 should be prioritised for  
106       vaccination.

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

## 126 **Introduction**

127       The omicron variant of SARS-CoV-2 led to a surge in cases among young people  
128 during 2022 when several countries lifted or alleviated their restrictions.[1] Although clinical  
129 trials showed that the BNT162b2 and mRNA-1273 vaccines had acceptable safety profiles in  
130 adolescents and reduced the risk of infection in the short-term,[2, 3] these trials were  
131 conducted before the emergence of omicron. Limited sample sizes also hindered the  
132 evaluation of the level of protection against severe COVID-19, such as hospitalisation, which  
133 could be estimated using large-scale observational studies. These studies also offer the  
134 possibility of investigating any potential links between vaccination and rare serious adverse  
135 events, such as myocarditis, for which the data appear inconsistent.[4, 5]

136       Currently, there is limited data on vaccine effectiveness (VE) against severe COVID-19  
137 caused by the omicron variant among adolescents. Two case-control studies found that two  
138 doses of the BNT162b2 mRNA vaccine had about 80% VE against COVID-19 hospitalisation  
139 or death in adolescents.[6] [7] However, given their study design, it is difficult to determine  
140 how common severe disease is during the omicron era. In addition, little is known about  
141 whether certain groups of adolescents should be prioritized for vaccination because of a  
142 higher risk of severe COVID-19, and whether vaccination has a similarly protective effect in  
143 such risk groups. Moreover, although a third dose, also known as a booster dose, may  
144 increase protection against symptomatic omicron infection in adolescents,[8, 9] the risk of  
145 severe COVID-19 after a third dose relative to after the second dose is unclear.

146       Therefore, the present study leveraged Swedish nationwide registers to evaluate, among  
147 adolescents, 1) the risk of serious adverse events following COVID-19 mRNA vaccination,  
148 and 2) the effectiveness of COVID-19 mRNA vaccination against hospitalisation due to  
149 COVID-19 and risk factors for COVID-19 hospitalisation during an omicron predominant  
150 period.

## 151 **Methods**

### 152 **Study design and cohorts**

153 This nationwide, retrospective cohort study was approved by the Swedish Ethical  
154 Review Authority (number 00094/2021), who waived the requirement of obtaining informed  
155 consent given the retrospective study design.

156 The cohort considered for inclusion was compiled by Statistics Sweden ([www.SCB.se](http://www.SCB.se));  
157 the government agency in charge of nationwide statistics in different areas and covering the total  
158 population of Sweden. All individuals born 2003-2009 who were given at least one dose of  
159 COVID-19 vaccine or had a documented SARS-CoV-2 infection until March 2022 were  
160 considered for inclusion (N=692,333). To these individuals, Statistics Sweden matched one  
161 control individual on birth year, sex, and municipality. Controls could not have a documented  
162 SARS-CoV-2 infection at the date of documented infection in the corresponding infected  
163 individual, and they could not have received a first dose of vaccine at the date when the  
164 corresponding vaccinated individual had received two doses of vaccine. The cohort was  
165 updated with vaccination data and SARS-CoV-2 infections until 2 June 2022. Because one  
166 control could be matched to several vaccinated individuals, the total eligible cohort consisted  
167 of 844,511 individuals, of whom 645,489 had been vaccinated with at least one dose, 600,846  
168 had been vaccinated with two doses, and 60,475 had been vaccinated with at least three doses  
169 (Figure 1). After excluding a few individuals vaccinated with a vector-based vaccine  
170 (N=134), a total of 844,377 individuals remained and were included in the present study for  
171 two sets of analyses. In a first set of analyses, named the safety analysis, all diagnoses set  
172 during hospitalisation were evaluated in all individuals given at least one dose of vaccine  
173 during follow-up (N=645,355) as compared to individuals never vaccinated during follow-up  
174 (N=199,022). In a second set of analyses, VE against COVID-19 hospitalisation was  
175 evaluated by comparing individuals given at least two doses of vaccine (N=501,945) to

176 individuals never vaccinated during follow-up (N=170,083), excluding all individuals with a  
177 previous documented SARS-CoV-2 infection (Figure 1). Data on individuals vaccinated  
178 against COVID-19 and data on documented SARS-CoV-2 infections were collected from the  
179 Swedish Vaccination Register and the SmiNet register, respectively. Both these registers are  
180 managed by the Public Health Agency of Sweden and all healthcare providers in Sweden  
181 were obliged to report to these registers according to law.[10, 11]

182

### 183 **Outcomes**

184 In the safety analysis, based on all diagnoses set in the cohort during the hospital stay  
185 until 5 June 2022, results are presented for 30 different diagnoses. These diagnoses were  
186 selected based on their incidence and general interest given previous reports of links between  
187 certain diagnoses and COVID-19 mRNA vaccination.[4, 12, 13] Only the first diagnosis was  
188 evaluated for each individual, and individuals with this diagnosis at baseline were therefore  
189 excluded from the prospective analyses.

190 In the VE analysis, the primary outcome was a main diagnosis of COVID-19 (thus,  
191 “due to” COVID-19 rather than “with” COVID-19), set during inpatient hospital stay from 1  
192 January 2022 until 5 June 2022. The secondary outcome was documented SARS-CoV-2  
193 infection of any severity from the SmiNet register, from 1 January 2022 until 28 February  
194 2022, as per when the guidelines for testing in Sweden had changed. For these two outcomes,  
195 only cases that occurred 7 days after the second dose of vaccine and onwards were counted to  
196 ensure the full effect of vaccination. The start of 1 January was selected on the basis that the  
197 omicron variant was first documented in Sweden on 29 November 2021[14] and by early  
198 January 2022 it represented >90% of sequenced cases (Supplementary Table 1). Data on all  
199 diagnoses used in this study were obtained from the National Patient Register[15] using 10<sup>th</sup>  
200 revision International Classification of Disease codes, starting from 1 January 2016 earliest



201 until 5 June 2022 latest. The definition and diagnostic codes for all diagnoses considered in  
202 the safety analysis and for the analysis of risk factors for COVID-19 hospitalisation are shown  
203 in Table 1. The positive predictive value for diagnoses set within the National Patient Register  
204 differs, but has generally been found to be between 85-95%, although sensitivity is often  
205 lower.[15] Finally, data on death due to COVID-19 or influenza, defined as death within 30  
206 days after the diagnosis, were obtained from the National Cause of Death Register.[16] The  
207 present study was approved by the Swedish Ethical Review Authority.

208

### 209 **Statistical analysis**

210 In the safety analysis, diagnoses were evaluated before and after the first dose of  
211 vaccine in 645,355 individuals given at least one dose of vaccine and in 199,022 controls who  
212 were unvaccinated during the follow-up time. The baseline date in vaccinated individuals was  
213 the date of vaccination with the first dose. In the controls, a baseline date was randomly  
214 assigned based on the mean baseline date and standard deviation among the vaccinated  
215 individuals (10 October 2021  $\pm$  54 days). Student's t-tests and chi-square tests were used to  
216 compare the prevalence of different variables at baseline. To estimate hazard ratios (HRs) for  
217 the 30 different diagnoses during follow-up, Cox regression models were used. Individuals  
218 were censored on the date of the diagnosis of interest, death, or end of follow-up (5 June  
219 2022), whichever came first.

220 In the VE analysis, logistic regression was used to estimate odds ratios (OR) for the  
221 primary outcome of COVID-19 hospitalisation (from 1 January 2022 until 5 June 2022), and  
222 for the secondary outcome of a SARS-CoV-2 infection (from 1 January 2022 until 28  
223 February 2022). The ORs obtained were used to estimate VE as 1 minus the OR x 100. In all  
224 analyses, the first model was unadjusted and the second model was adjusted for baseline date,  
225 age, sex, and whether the individual was born in Sweden or not. Data underlying these

226 covariates were retrieved from Statistics Sweden.[17] To investigate whether VE differed by  
227 the covariates, interaction analyses were performed using product terms created by  
228 multiplying the variable coding for vaccination status at baseline (vaccinated/unvaccinated)  
229 by each respective covariate, which was added to the logistic regression model. Given that the  
230 interaction term was statistically significant ( $P < 0.05$ ) for the baseline date, VE was also  
231 estimated in subgroups according to this covariate. The number needed to vaccinate (NNV)  
232 with two doses to prevent one case of COVID-19 hospitalisation during follow-up was  
233 estimated as the inverse of the absolute risk difference between the groups  
234 (vaccinated/unvaccinated). The NNV was estimated both in the total cohort and by subgroups.

235 Finally, a sensitivity analysis using a negative control outcome was conducted to  
236 explore the potential risk of bias due to unmeasured confounding.[18] Here, a logistic  
237 regression model was performed, comparing individuals given at least two doses of COVID-  
238 19 mRNA vaccine compared to never vaccinated individuals concerning the outcome of  
239 hospitalisation due to influenza from 1 January 2022 until 5 June 2022. All analyses were  
240 performed in SPSS v29.0 for Mac (IBM Corp, Armonk, NY, USA), and Stata v16.1 for Mac  
241 (Statcorp, College Station, Texas, USA). A two-sided P-value  $< 0.05$  or Ors/HRs with 95%  
242 CIs not crossing one were considered statistically significant.

243

#### 244 **Role of the funding source**

245 The present study was not funded.

246

#### 247 **Results**

248 The total cohort comprised 844,377 adolescents born 2003-2009 (age 11.3-19.2 years),  
249 of whom 645,355 received at least one dose of COVID-19 mRNA vaccine and 199,022 never  
250 vaccinated individuals (controls). Almost 90% of the vaccinated individuals received

251 BNT162b2 as a first dose, while the remaining received mRNA-1273. Baseline characteristics  
252 are shown in Table 1. Individuals that were never vaccinated were slightly younger, more  
253 often of male sex and born outside of Sweden, and were less often diagnosed with a previous  
254 SARS-CoV-2 infection ( $P<0.001$  for all). Concerning other diagnoses at baseline, differences  
255 between the groups were marginal (Table 1).

256

### 257 **Serious adverse events after a first dose of vaccine**

258 In the safety analysis ( $N=844,377$ ), there were a total of 19,660 hospitalisations among  
259 14,320 individuals during follow-up. In vaccinated individuals, 1.69% ( $N=10,918$ ) were  
260 hospitalised at least once, compared to 1.71% ( $N=3,402$ ) in those never vaccinated ( $P=0.29$   
261 for difference). There were marginal differences between the two groups in the 30 diagnoses  
262 presented (Table 2), although statistically significant associations in favour of vaccination  
263 were observed with respect to the risk of sepsis, thrombocytopenia, alcohol dependency, and  
264 Crohn's disease ( $P<0.05$  for all). None of the other associations were statistically significant.

265

### 266 **Vaccine effectiveness against COVID-19 hospitalisation**

267 In the analysis of VE against COVID-19 hospitalisation, 501,945 individuals vaccinated  
268 with two doses and 170,083 never vaccinated controls were included. Between 1 January  
269 2022 and 5 June 2022, a total of 47 individuals (6 per 100,000) were hospitalised due to  
270 COVID-19. Of these, 21 cases were among those vaccinated with two doses (0.004%), and 26  
271 among unvaccinated (0.015%), resulting in a VE of 75% (95% CI, 54-86,  $P<0.001$ ) (Table 3).  
272 The NNV with two doses to prevent one case of COVID-19 hospitalisation was 9,007. For  
273 those with a second dose of vaccine earlier than 15 November, the VE was 68% (95% CI, 25-  
274 86,  $P=0.009$ ), compared to 86% (95% CI, 63-95,  $P<0.001$ ) for those with a second dose of  
275 vaccine 15 November 2021 and later ( $P=0.03$  for interaction). When comparing individuals

276 vaccinated with three doses (N=41,225) compared to those vaccinated with two doses  
277 (N=413,544), only 12 individuals were hospitalised due to COVID-19 during follow-up (VE,  
278 13%, 95% CI, -354-84, P=0.86). There were no deaths within 30 days of hospitalisation  
279 among the 238 individuals hospitalised due to COVID-19 in the total cohort (N=844,377)  
280 since the beginning of the pandemic in January 2020.

281

## 282 **Risk factors for COVID-19 hospitalisation and vaccine effectiveness by subgroups**

283 Of the 47 individuals hospitalised due to COVID-19 in the VE analysis, 28 (60%) had  
284 previously been hospitalised for another condition, compared to 66,756 (10%) of the  
285 individuals in the rest of the cohort. Among the individuals hospitalised due to COVID-19, 15  
286 (32%) had previously been diagnosed with an infection, compared to 22,110 (3.3%) in the  
287 rest of the cohort, equal to an adjusted OR for COVID-19 hospitalisation of 14.3 (95% CI,  
288 7.7-26.6, P<0.001), after adjustment for age, sex, baseline date, vaccination status, and  
289 whether the individual was born in Sweden. The VE in this risk group was similar (VE, 88%,  
290 95% CI, 57-96, P<0.001), as in the total cohort, but with a slightly lower vaccination  
291 coverage (72.7% vs. 74.7%). In addition, 15 (32%) of the individuals hospitalised due to  
292 COVID-19 had previously been diagnosed with cerebral palsy and/or different development  
293 disorders, compared to 25,947 individuals (3.9%) in the rest of the cohort, resulting in an  
294 adjusted OR for COVID-19 hospitalisation of 12.0 (95% CI, 6.4-22.6, P<0.001). Again, VE  
295 in this subgroup was similar as in the total cohort (VE, 72%, 95% CI, 18-90, P=0.02), but  
296 with a slightly lower vaccination coverage (71.5% vs 74.8%). The NNV with two doses to  
297 prevent one case of COVID-19 hospitalisation in the subgroup of individuals previously  
298 diagnosed with infections or development disorders (N=46,783) was 1,031.

299

## 300 **Vaccine effectiveness against SARS-CoV-2 infection**

301 The VE against SARS-CoV-2 infection of any severity was estimated among 488,441  
302 individuals vaccinated with two doses compared to 165,626 never vaccinated controls.  
303 Between 1 January 2022 and 28 February 2022, there were 72,631 cases of confirmed SARS-  
304 CoV-2 infection. The VE varied by time since the last dose ( $P<0.001$ ), with no VE in the total  
305 cohort (VE, -2%, 95% CI, -4-0,  $P=0.02$ ) (Table 4). There was a marginal VE among  
306 individuals with a second dose no earlier than 1 September 2021 (VE, 4%, 95% CI, 2-6,  
307  $P<0.001$ ), a low VE for individuals with a second dose no earlier than 1 November 2021 (VE,  
308 21%, 95% CI, 19-23,  $P<0.001$ ), and a moderate VE for individuals with a second dose no  
309 earlier than 1 January 2022 (VE, 47%, 95% CI, 43-51,  $P<0.001$ ).

310

### 311 **Sensitivity analysis**

312 The risk of hospitalisation due to influenza was evaluated in 600,021 individuals given at  
313 least two doses of vaccine compared to in 199,003 never vaccinated individuals. Between 1  
314 January 2022 and 5 June 2022, a total of 48 individuals (6 per 100,000) were hospitalised due  
315 to influenza, with no detectable VE (VE, -6%, 95% CI, -51-119,  $P=0.88$ ). Of the 130  
316 individuals in the total cohort hospitalised for influenza since the start of the COVID-19  
317 pandemic in January 2020, one individual died within 30 days of hospitalisation.

318

### 319 **Discussion**

320 In this nationwide study of more than 0.8 million adolescents, COVID-19 mRNA  
321 vaccination was not associated with an increased risk of hospitalisation for any diagnosis,  
322 with an overall risk of hospitalisation which was similar in vaccinated and unvaccinated  
323 individuals. The results also showed that although vaccination was associated with lower risk  
324 of COVID-19 hospitalisation during an omicron predominant period, the absolute risk of

325 being hospitalised was extremely low, except in subgroups of adolescents that had previously  
326 been diagnosed with infections, cerebral palsy or other development disorders.

327 Evidence on the safety and effectiveness of COVID-19 mRNA vaccination in  
328 adolescents during the omicron predominant period is limited. In this study, no association  
329 between vaccination and increased risk of hospitalisation in general, or for any specific  
330 diagnosis, was detected. This suggests that COVID-19 vaccination in adolescents is safe.  
331 These findings add to, and extend upon those from a nationwide study in Scotland, reporting  
332 no association between vaccination and increased risk of hospital stay for 17 different  
333 diagnoses among adolescents.[5] The present study also estimated that two doses of mRNA  
334 vaccine had about 75% effectiveness against hospitalisation due to COVID-19. Similar  
335 estimates were reported in two case-control studies of adolescents conducted in the US and  
336 Brazil during an omicron predominant period, where VE against COVID-19 hospitalisation or  
337 death was about 80%.[6] [7] However, given their design, these studies were unable to  
338 determine how common severe COVID-19 is. Therefore, the very low absolute risk of severe  
339 disease observed in the present cohort study based on a nationwide sample of adolescents is  
340 an important finding for decision making concerning the need for COVID-19 vaccination in  
341 adolescents. Overall, only 47 individuals, or 6 in 100,000, were hospitalised due to COVID-  
342 19 during a period of 5 months, and none of all adolescents hospitalised due to COVID-19  
343 since the start of the pandemic died within 30 days of hospitalisation. Based on this very low  
344 risk of severe COVID-19 in the total cohort, the NNV with two doses to prevent one case  
345 during follow-up was about 9,000. Interestingly, the absolute risk of being hospitalised due to  
346 COVID-19 and influenza was similar, despite that the infection pressure from SARS-CoV-2  
347 during follow-up was more than 100 times higher than that of influenza.[19]

348 Given the above, it is important to evaluate whether certain groups of adolescents are at  
349 higher risk of severe COVID-19, and if so, whether vaccination is associated with similar

350 protection among these individuals. This study identified two different clusters of diagnoses  
351 which increased the risk of COVID-19 hospitalisation more than tenfold. The first included  
352 previous infections and the second included cerebral palsy and other developmental disorders.  
353 An encouraging finding was that the VE in these subgroups was similar to that in the total  
354 cohort, and consequently, the NNV to prevent one case of COVID-19 hospitalisation was  
355 about 1,000 individuals. It is therefore of concern that vaccination coverage in these risk  
356 groups was somewhat lower compared to in the total cohort. Although we are unable to  
357 determine the underlying causes for this observation, factors such as recurrent infections  
358 interfering with the administration of the vaccine, and fear of adverse events, may have  
359 contributed. Taken together, these findings suggest that vaccination of adolescents during the  
360 omicron era should primarily be targeting risk groups, such as those with previous infections  
361 and development disorders.

362 Concerning the outcome of SARS-CoV-2 infection of any severity, the results indicated  
363 that VE from primary vaccination wanes within a few months, similar to observations made  
364 in a few other countries.[7-9] However, there is a lack of data exploring whether booster  
365 doses reduce the risk of severe COVID-19 as compared to primary vaccination.[20] The  
366 results for this comparison in the present study showed that COVID-19 hospitalisations  
367 during follow-up were once again extremely rare, implying that administration of booster  
368 doses to the general population of adolescents may not be warranted at the current stage of the  
369 pandemic. Based on these findings, it is noteworthy that the US and several countries in  
370 Europe are recommending booster doses to adolescents.[21, 22]

371 The present study has limitations that should be considered. Because of the  
372 observational design, conclusions based on the associations found should be made with  
373 caution. For example, despite that VE changed marginally before and after adjustment for  
374 covariates, there may be other factors that could have influenced the estimates. However, for

375 the analysis of serious adverse events, we evaluated all diagnoses set during hospital stay both  
376 before and after the first dose of vaccine, thereby increasing the chance of detecting selection  
377 bias that could interfere with the results. In addition, the sensitivity analysis wherein influenza  
378 was used as a negative control outcome supported the lack of important confounding.  
379 Moreover, because COVID-19 hospitalisation in this population was very rare, it was not  
380 possible to estimate the VE of a first booster dose in this cohort with any form of precision.  
381 Strengths of this study include that all the registers used to obtain the data used in the present  
382 study have nationwide coverage with virtually zero loss to follow-up. Finally, the study  
383 cohort was based on the total population of Swedish adolescents, including 0.8 million  
384 individuals aged 11-19 years of age, which increases the possibility to generalize the findings  
385 to other countries with similar population structures.

386

## 387 **Conclusion**

388 In summary, COVID-19 mRNA vaccination was not associated with an increased risk  
389 for hospitalisation of any cause in adolescents, suggesting that they are safe to use. While  
390 vaccination was associated with a reduced risk of COVID-19 hospitalisation during the  
391 omicron era, the absolute risk among general adolescents was extremely low and similar to  
392 that of influenza. In contrast, in a large proportion of adolescents hospitalised due to COVID-  
393 19, certain risk factors were present, and the effectiveness of vaccination in these individuals  
394 was similar to in the total cohort. These results indicate that certain vulnerable subgroups of  
395 adolescents, rather than adolescents in general, should be prioritized for vaccination.

396

## 397 **Contributors**

398 PN conceived and designed the study. PN acquired the data. PN performed the  
399 statistical analyses. PN and MB accessed and verified the underlying data. All authors



400 interpreted the data. PN and MB drafted the manuscript. All authors critically revised the  
401 manuscript for intellectual content. PN and AN supervised the work. All authors gave final  
402 approval of the version to be published. All authors had full access to all the data and had  
403 final responsibility for the decision to submit for publication

404

## 405 **Declaration of interests**

406 We declare no competing interests.

407

## 408 **Role of the funding source**

409 There was no funding source for this study.

410

## 411 **Data sharing statement**

412 The data files used for the present study are publicly unavailable according to  
413 regulations under Swedish law. However, all data used for the present study can be applied  
414 for from the National Board of Health and Welfare, Statistics Sweden, and the Public Health  
415 Agency of Sweden.

416

## 417 **References**

- 418 1. World Health Organization. Interim statement on COVID-19 vaccination for  
419 children. Available from: [https://www.who.int/news/item/11-08-2022-interim-statement-](https://www.who.int/news/item/11-08-2022-interim-statement-on-covid-19-vaccination-for-children)  
420 [on-covid-19-vaccination-for-children](https://www.who.int/news/item/11-08-2022-interim-statement-on-covid-19-vaccination-for-children). Accessed 20 Sep, 2022.
- 421 2. Frenck RW, Jr., Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, et al.  
422 Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N  
423 Engl J Med. 2021;385(3):239-50. Epub 2021/05/28. doi: 10.1056/NEJMoa2107456. PubMed  
424 PMID: 34043894; PubMed Central PMCID: PMC8174030.
- 425 3. Ali K, Berman G, Zhou H, Deng W, Faughnan V, Coronado-Voges M, et al.  
426 Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. N Engl J Med.  
427 2021;385(24):2241-51. Epub 2021/08/12. doi: 10.1056/NEJMoa2109522. PubMed PMID:  
428 34379915; PubMed Central PMCID: PMC8385554.


- 429 4. Mevorach D, Anis E, Cedar N, Hasin T, Bromberg M, Goldberg L, et al.  
430 Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. *N Engl J Med*.  
431 2022;386(10):998-9. Epub 2022/01/27. doi: 10.1056/NEJMc2116999. PubMed PMID:  
432 35081295; PubMed Central PMCID: PMCPMC8823652.
- 433 5. Rudan I, Millington T, Antal K, Grange Z, Fenton L, Sullivan C, et al. BNT162b2  
434 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people  
435 aged 12-17 years in Scotland. *The Lancet Regional Health – Europe*. 2022;23. doi:  
436 10.1016/j.lanepe.2022.100513.
- 437 6. Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al.  
438 BNT162b2 Protection against the Omicron Variant in Children and Adolescents. *N Engl J*  
439 *Med*. 2022;386(20):1899-909. Epub 2022/03/31. doi: 10.1056/NEJMoa2202826. PubMed  
440 PMID: 35353976; PubMed Central PMCID: PMCPMC9006785.
- 441 7. Florentino PTV, Millington T, Cerqueira-Silva T, Robertson C, de Araujo Oliveira  
442 V, Junior JBS, et al. Vaccine effectiveness of two-dose BNT162b2 against symptomatic and  
443 severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-  
444 control study. *Lancet Infect Dis*. 2022. Epub 2022/08/12. doi: 10.1016/S1473-  
445 3099(22)00451-0. PubMed PMID: 35952702; PubMed Central PMCID: PMCPMC9359673  
446 programme from JBS SA. VdAO, VSB, MLB, and MB-N are employees of Fiocruz, a federal  
447 public institution that manufactures Vaxzevria in Brazil through a full technology transfer  
448 agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry  
449 of Health for public health use. SVK was Co-Chair of the Scottish Government's Expert  
450 Reference Group on Ethnicity and COVID-19 and a member of the UK Government's  
451 Scientific Advisory Group on Emergencies subgroup on ethnicity. IR is a member of the  
452 Scientific Advisory Committee of the Government of Croatia and co-Editor-in-Chief of the  
453 *Journal of Global Health*. CRS declares funding from the Medical Research Council, the  
454 National Institute for Health Research, the Chief Scientist Office, and the New Zealand  
455 Ministry for Business, Innovation and Employment and Health Research Council during the  
456 conduct of this study. CR declares he is a Member of SPI-M, Scottish Government Scientific  
457 Advisory Committee, MHRA COVID-19 vaccine benefit and risk expert working group. AS  
458 declares that he is a member of the UK and Scottish Governments COVID-19 Advisory Boards  
459 and Astra-Zeneca's Thrombotic Thrombocytopenic Taskforce. IR is Co-Editor-in-Chief of the  
460 *Journal of Global Health* and President of the International Society of Global Health. All other  
461 authors declare no competing interests.
- 462 8. Fleming-Dutra KE, Britton A, Shang N, Derado G, Link-Gelles R, Accorsi EK, et al.  
463 Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2  
464 Infection in Children and Adolescents During Omicron Predominance. *JAMA*.  
465 2022;327(22):2210-9. Epub 2022/05/14. doi: 10.1001/jama.2022.7493. PubMed PMID:  
466 35560036; PubMed Central PMCID: PMCPMC9107063.
- 467 9. Tartof SY, Frankland TB, Slezak JM, Puzniak L, Hong V, Xie F, et al. Effectiveness  
468 Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care  
469 Encounters for Delta and Omicron SARS-CoV-2 Infection Among Adolescents Aged 12 to 17  
470 Years. *JAMA Netw Open*. 2022;5(8):e2225162. Epub 2022/08/04. doi:  
471 10.1001/jamanetworkopen.2022.25162. PubMed PMID: 35921109; PubMed Central PMCID:  
472 PMCPMC9350713.
- 473 10. Public Health Agency of Sweden. The National Vaccination Register. Available  
474 from: <https://www.folkhalsomyndigheten.se/smittskydd-beredskap/vaccinationer/nationella-vaccinationsregistret/>. Accessed 20 Sep, 2022.
- 475

- 476 11. Public Health Agency of Sweden. SmiNet. Available from:  
477 <https://www.folkhalsomyndigheten.se/smittskydd-beredskap/overvakning-och->  
478 [rapportering/sminet/](https://www.folkhalsomyndigheten.se/smittskydd-beredskap/overvakning-och-rapportering/sminet/). Accessed 20 Sep, 2022.
- 479 12. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of  
480 myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study  
481 in claims databases. *Lancet*. 2022;399(10342):2191-9. Epub 2022/06/13. doi:  
482 10.1016/S0140-6736(22)00791-7. PubMed PMID: 35691322; PubMed Central PMCID:  
483 PMCPMC9183215 KLA and JDS own stock in UnitedHealth Group. All other authors declare  
484 no competing interests.
- 485 13. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of  
486 the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. *N Engl J Med*.  
487 2021;385(12):1078-90. Epub 2021/08/26. doi: 10.1056/NEJMoa2110475. PubMed PMID:  
488 34432976; PubMed Central PMCID: PMCPMC8427535.
- 489 14. Public Health Agency of Sweden. New virus variant of SARS-CoV-2 also in  
490 Sweden.  
491 [https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/november/ny-](https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/november/ny-virusvariant-av-sars-cov-2-aven-i-sverige/)  
492 [virusvariant-av-sars-cov-2-aven-i-sverige/](https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2021/november/ny-virusvariant-av-sars-cov-2-aven-i-sverige/). Accessed 29 March 2022.
- 493 15. Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, et al.  
494 External review and validation of the Swedish national inpatient register. *BMC Public Health*.  
495 2011;11:450. Epub 2011/06/09. doi: 10.1186/1471-2458-11-450. PubMed PMID: 21658213;  
496 PubMed Central PMCID: PMCPMC3142234.
- 497 16. Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, et al.  
498 The Swedish cause of death register. *European journal of epidemiology*. 2017;32(9):765-73.
- 499 17. Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Michaëlsson K, Neovius M, et  
500 al. Registers of the Swedish total population and their use in medical research. *European*  
501 *Journal of Epidemiology*. 2016;31(2):125-36. doi: 10.1007/s10654-016-0117-y.
- 502 18. World Health Organization. Evaluation of COVID-19 vaccine effectiveness.  
503 Interim guidance. March 17, 2021. Available from:  
504 <https://apps.who.int/iris/handle/10665/340301>. Accessed 20 Sep, 2022.
- 505 19. Public Health Agency of Sweden. Influenzasäsongen 2021-2022. Available from:  
506 [https://www.folkhalsomyndigheten.se/contentassets/a9433fcec24c788e11ea0d47fdf21b](https://www.folkhalsomyndigheten.se/contentassets/a9433fcec24c788e11ea0d47fdf21b/influenzasasongen-2021-2022-sasongssammanfattning-final.pdf)  
507 [/influenzasasongen-2021-2022-sasongssammanfattning-final.pdf](https://www.folkhalsomyndigheten.se/contentassets/a9433fcec24c788e11ea0d47fdf21b/influenzasasongen-2021-2022-sasongssammanfattning-final.pdf). Accessed 29 Sep, 2022.
- 508 20. Chiew CJ, Premikha M, Chong CY, Wei WE, Ong B, Lye DC, et al. Effectiveness of  
509 primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation  
510 among adolescents aged 12-17 years in Singapore: a national cohort study. *The Lancet*  
511 *Infectious Diseases*. 2022. doi: 10.1016/S1473-3099(22)00573-4.
- 512 21. Centers for Disease Control and Prevention. Stay Up to Date with COVID-19  
513 Vaccines Including Boosters. Available from: [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html)  
514 [ncov/vaccines/stay-up-to-date.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html). Accessed 30 Sep, 2022.
- 515 22. European Centre for Disease Prevention and Control. COVID-19 vaccine  
516 effectiveness in adolescents aged 12–17 years and interim public health considerations for  
517 administration of a booster dose. 8 February 2022. Available from:  
518 [https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-considerations-for-](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-considerations-for-booster-doses-in-adolescents-Feb%202022.pdf)  
519 [booster-doses-in-adolescents-Feb%202022.pdf](https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-considerations-for-booster-doses-in-adolescents-Feb%202022.pdf). Accessed 30 Sep, 2022.
- 520

## 521 **Figure legends**

522 **Figure 1.** Selection of study participants.

523



medRxiv preprint doi: <https://doi.org/10.1101/2022.10.19.22281286>; this version posted October 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1